Burning Rock Biotech (BNR) Cash & Equivalents (2021 - 2023)

Burning Rock Biotech has reported Cash & Equivalents over the past 3 years, most recently at $85.4 million for Q4 2023.

  • Quarterly results put Cash & Equivalents at $85.4 million for Q4 2023, down 32.9% from a year ago — trailing twelve months through Dec 2023 was $85.4 million (down 32.9% YoY), and the annual figure for FY2023 was $86.6 million, down 35.76%.
  • Cash & Equivalents for Q4 2023 was $85.4 million at Burning Rock Biotech, down from $127.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for BNR hit a ceiling of $223.9 million in Q4 2021 and a floor of $85.4 million in Q4 2023.
  • Median Cash & Equivalents over the past 3 years was $127.3 million (2022), compared with a mean of $145.5 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 43.13% in 2022 and later crashed 32.9% in 2023.
  • Burning Rock Biotech's Cash & Equivalents stood at $223.9 million in 2021, then tumbled by 43.13% to $127.3 million in 2022, then plummeted by 32.9% to $85.4 million in 2023.
  • The last three reported values for Cash & Equivalents were $85.4 million (Q4 2023), $127.3 million (Q4 2022), and $223.9 million (Q4 2021) per Business Quant data.